Medical technology leader Halozyme’s stock is back in a buy zone. The biopharma company gave robust 2027 and 2028 sales forecasts.
Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we … [1013 chars]
Source: Investor’s Business Daily | Published: 2026-02-05T14:55:47Z
Credit: Investor’s Business Daily
